Immusoft’s ISP-002 Earns FDA Rare Pediatric Disease Designation for MPS II, Enabling Potential Priority Review Voucher
Immusoft’s investigational engineered B cell therapy ISP-002 received FDA Rare Pediatric Disease designation for treating mucopolysaccharidosis type II (Hunter syndrome), making the program eligible for a Priority Review Voucher upon approval. ISP-002 is designed to use patients’ own B cells to continuously produce iduronate-2-sulfatase (IDS) as an alternative to frequent enzyme replacement infusions.